Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q2 2024 (June 30)11holders −1
1new positions
2sold out
$0.05avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, down 1 from Q1 2024. 1 opened new positions and 2 sold out. The largest holders were LMR Partners LLP ($26K), Shaolin Capital Management LLC ($12K) and Morgan Stanley ($7K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3 |
| Exits | 2 | $486 |
All 13F filers, Q1 2024 → Q2 2024: 156 shares bought and 66,252 shares sold, net −66,096 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| LMR Partners LLP | — | No change | 539,588 | $26K |
| Shaolin Capital Management LLC | — | Reduce -15.0% | 249,143 | $12K |
| Morgan Stanley | — | Reduce -1.7% | 146,439 | $7K |
| Yakira Capital Management, Inc. | — | No change | 108,485 | $5K |
| Walleye Capital LLC | — | No change | 23,258 | $1K |
| Walleye Trading LLC | — | No change | 15,505 | $735 |
| Wolverine Asset Management LLC | — | Reduce -32.8% | 15,319 | $726 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $50 |
| Bank of America Corp. | — | Add +100.0% | 200 | $9 |
| UBS Group AG | — | New | 56 | $3 |
| Tower Research Capital LLC (TRC) | — | No change | 48 | $2 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.